CLINICAL_TRIALS
trial_result
· 2018-10-02
Clinical Trial Update: Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis [Phase 2]
Summary
Phase 2 trial of JBT-101 in diffuse cutaneous systemic sclerosis was terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Corbus Pharmaceuticals Inc. | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2018-10-02